Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial

The prospective multicentre Phase II PTLD-2 trial (NCT02042391) tested modified risk-stratification in adult SOT recipients with CD20-positive PTLD based on principles established in the PTLD-1 trials: sequential treatment and risk-stratification. After rituximab monotherapy induction, patients in c...

Descripción completa

Detalles Bibliográficos
Autores principales: Zimmermann, Heiner, Koenecke, Christian, Dreyling, Martin H., Pott, Christiane, Dührsen, Ulrich, Hahn, Dennis, Meidenbauer, Norbert, Hauser, Ingeborg A., Rummel, Mathias J., Wolf, Dominik, Heuser, Michael, Schmidt, Christian, Schlattmann, Peter, Ritgen, Matthias, Siebert, Reiner, Oschlies, Ilske, Anagnostopoulos, Ioannis, Trappe, Ralf U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9522585/
https://www.ncbi.nlm.nih.gov/pubmed/35974101
http://dx.doi.org/10.1038/s41375-022-01667-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9522585/
https://www.ncbi.nlm.nih.gov/pubmed/35974101
http://dx.doi.org/10.1038/s41375-022-01667-1

Ejemplares similares